Call

COYOTE Study

On This Page:

Blood gluocse sensor

Comparing Automated Insulin Delivery System to Usual Insulin Therapy in Adults Living with Type 2 Diabetes.

Purpose

We are inviting people living with type 2 diabetes to participate in a study looking at whether the automated insulin delivery system (CamAPS, HX), can help improve management of blood glucose levels compared to people’s usual insulin therapy when used in combination with a glucose sensor.

Who can take part?

You may be eligible to participate if you are:

  • Aged 18 years or older
  • Have been living with type 2 diabetes for at least 12 months
  • Use insulin injections to manage your diabetes
  • Have an HbA1c of 15% or below

What does participation involve?

Participation in the study is over a period of approximately 7 months and includes:

  • 5 in-person visits at St Vincent’s Public Hospital, Melbourne
  • Additional remote phone check-ins

You will need to provide blood and urine samples, answer questions about your medical history, complete questionnaires and wear glucose sensors.

If you are eligible to participate, you will be randomly assigned into one of two study groups:

  • Group 1: Use the CamAPS HX automated insulin delivery system (Ypsomed insulin pump)
  • Group 2: Continue your usual insulin therapy, along with a glucose sensor

Reimbursement

There are no additional costs to you as a participant in the study.

As an appreciation for your time and participation, you will be reimbursed $160 in total upon completion of all study activities.

Site Location

  • St Vincent’s Public Hospital, Melbourne.

Contact

Diabetes Technology Research Group Melbourne via email dtrg-t1research@unimelb.edu.au or call on 03 9231 2757.

This study has received ethical approval from the St Vincent’s Hospital Melbourne (Public) Human Research Ethics Committee ref# 172/25

Skip to content